Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Your search for "Results" return 76 results.
Tildren® receives FDA approval to control clinical signs of Navicular Syndrome >
Tildren® is now available in the US
Egypt study confirms that a single rHVT-H5 hatchery vaccination could be an effective tool to address A/H5N1 prevention >
Research confirms that in endemic countries the classical inactivated vaccines are less effective and hard to administer, while application of a rHVT vector hatchery vaccine is labour saving, cost eff...
Ceva merges all R&D activity and nominates Dr. Steve Chu as member of the Executive Committee >
Libourne 4th September 2014 - Ceva Santé Animale announced the appointment of Dr.Chu to its executive committee with responsibility for all R&D activities. The move recognises the growing importan...
Mid-year results >
Ceva attracts strong investor support for 4th LMBO and returns to double-digit growth in first 6 months of 2014
New C.H.I.C.K. Program application for hatchery vaccination services >
Ceva boosts its hatchery vaccination services with powerful new C.H.I.C.K. Program app.
Cooperation between Veterinary Department of Myanmar and Ceva Santé Animale >
Towards a bilateral cooperation between the Livestock Breeding and Veterinary Department of Myanmar and Ceva Santé Animale
Ceva proposes new respiratory health programs for swine >
Symposium held prior to ESPHM presents benefits of more targeted vaccination
Ceva hosts 2nd. Biotech Innovation day in the US >
Industrial know-how partners emphasize benefits of working together
Ceva stresses the need for more INNOVATION in the hatchery to drive growing global demand for poultry meat >
Company launches Cevac IBird ® a live, attenuated IB vaccine, to add to its portfolio of 16 new technology vaccines
Ceva’s growth continues despite difficult market conditions >
Libourne, France, 22 July, 2013: Consolidated sales of the Ceva Group reached €310m in the first 6 months of 2013, up by 2%, 4.2% on the previous year at a constant perimeter and exchange rates. C...